Press Releases :: Algernon Pharmaceuticals Inc. (AGN)

Mar 01, 2021 7:00am EST

Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer

Feb 25, 2021 7:00am EST

Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference

Feb 19, 2021 8:00am EST

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

Feb 17, 2021 7:47am EST

Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data

Feb 10, 2021 7:00am EST

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

Feb 08, 2021 8:05am EST

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

Feb 03, 2021 8:00am EST

Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

Feb 01, 2021 7:30am EST

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”

Jan 22, 2021 12:14pm EST

Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants

Jan 19, 2021 11:59am EST

Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants

rss_feed News RSS

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company.

Sign up for our News Releases and Updates

Head Office

Suite 400 - 601 West Broadway
Vancouver, British Columbia V5Z 4C2

Follow Us On

© Algernon Pharmaceuticals Inc. - All Rights Reserved